[1]
|
Mayr VD, Dunser MW, Greil V, et al. Causes of death and determinants of outcome in critically ill patients[J]. Crit Care, 2006, 10:R154. doi: 10.1186/cc5086 |
[2]
|
De Backer D, Foulon P. Minimizing catecholamines and optimizing perfusion[J].Crit Care, 2019, 23:149. doi: 10.1186/s13054-019-2433-6 |
[3]
|
Jentzer JC, Coons JC, Link CB, et al. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit[J]. J Cardiovasc Pharmacol Ther, 2015, 20:249-246. doi: 10.1177/1074248414559838 |
[4]
|
Annane D, Ouanes-Besbes L, de Backer D, et al. A global perspective on vasoactive agents in shock[J]. Intensive Care Med, 2018, 44:833-846. doi: 10.1007/s00134-018-5242-5 |
[5]
|
De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock[J]. N Engl J Med, 2010, 362:779-789. doi: 10.1056/NEJMoa0907118 |
[6]
|
Hamzaoui O, Jozwiak M, Geffriaud T, et al. Norepinephrine exerts an inotropic effect at the early phase of human septic shock[J]. Br J Anaesth, 2018, 120:517-524. doi: 10.1016/j.bja.2017.11.065 |
[7]
|
De Backer D, Pinsky M. Norepinephrine improves cardiac function during septic shock, but why?[J].Br J Anaesth, 2018, 120:421-424. doi: 10.1016/j.bja.2017.11.069 |
[8]
|
Albanese J, Leone M, Garnier F, et al. Renal effects of norepinephrine in septic and nonseptic patients[J]. Chest, 2004, 126:534-539. doi: 10.1378/chest.126.2.534 |
[9]
|
Boerma EC, Ince C. The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients[J]. Intensive Care Med, 2010, 36:2004-2018. doi: 10.1007/s00134-010-1970-x |
[10]
|
Hamzaoui O, Scheeren TWL, Teboul JL.Norepinephrine in septic shock:when and how much?[J].Curr Opin Crit Care, 2017, 23:342-347. doi: 10.1097/MCC.0000000000000418 |
[11]
|
Martin C, Medam S, Antonini F, et al. Norepinephrine:not too much, too long[J]. Shock, 2015, 44:305-309. doi: 10.1097/SHK.0000000000000426 |
[12]
|
Tanja A, Treschan MD, Peters MD. The Vasopressin System[J].Anesthesiology, 2006, 105:599-612 doi: 10.1097/00000542-200609000-00026 |
[13]
|
Holmes CL, Landry DW, Granton JT. Science review:vasopressin and the cardiovascular system part 1-receptor physiology[J]. Crit Care, 2003, 7:427-434. doi: 10.1186/cc2337 |
[14]
|
James A, Russell MD, Keith R, et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock[J].N Engl J Med, 2008, 358:877-887. doi: 10.1056/NEJMoa067373 |
[15]
|
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign:international guidelines for management of sepsis and septicshock:2016[J]. Intensive Care Med, 2017, 43:304-377. doi: 10.1007/s00134-017-4683-6 |
[16]
|
Marks JA, Pascual JL. Selepressin in septic shock:Sharpening the VASST effects of vasopressin?[J].Crit Care Med, 2014, 42:1747-1748. doi: 10.1097/CCM.0000000000000420 |
[17]
|
Liu ZM, Chen J, Kou QY, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock:a multicentre, randomised, double-blinded trial[J].Intensive Care Med, 2018, 44:1816-1825. doi: 10.1007/s00134-018-5267-9 |
[18]
|
Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock:the vanish randomized clinical trial[J]. JAMA, 2016, 316:509-518. doi: 10.1001/jama.2016.10485 |
[19]
|
Scheeren TWL, Bakker J, De Backer D, et al. Current use of vasopressors in septic shock[J]. Ann Intensive Care, 2019, 9:20. doi: 10.1186/s13613-019-0498-7 |
[20]
|
Dietrich A, Mathia S, Kaminski H, et al. Chronic activation of vasopressin V2 receptor signalling lowers renal medullary oxygen levels in rats[J]. Acta Physiol (Oxf), 2013, 207:721-731. doi: 10.1111/apha.12067 |
[21]
|
Qiu X, Huang Y, Xu J, et al.Effects of terlipressin on microcirculation of small bowel mesentery in rats with endotoxic shock[J].J Surg Res, 2014, 188:503-509. http://www.ncbi.nlm.nih.gov/pubmed/24582066 |
[22]
|
Hall A, Busse LW, Ostermann M. Angiotensin in Critical Care[J]. Crit Care, 2018, 22:69. http://www.researchgate.net/publication/324074837_Angiotensin_in_Critical_Care |
[23]
|
Khanna A, English SW, Wang XS, et al. Angiotensin Ⅱ for the Treatment of Vasodilatory Shock[J]. N Engl J Med, 2017, 377:419-430. http://www.onacademic.com/detail/journal_1000040154977810_2eaf.html |